Experimental autoimmune encephalomyelitis (EAE) in female SJL mice

EAE, demyelination, immunisation
Figure 1: Serial coronal sections of the thoracic spinal cord from a mouse with a clinical score of 2.25. A: Luxol Fast Blue (LFB) stain. B: LFB + cresyl violet stain. C: LFB + hematoxylin and eosin stain. Blue = myelin, violet = cell nuclei, pink = cytoplasm. Arrow: demyelination in the white matter and infiltration of cells. Magnification: 10x. Scale bar: 300 µm.

Species

Mouse

Field of application:

EAE is induced by a single s.c. application of an emulsion containing Freund’s adjuvant, Proteolipidprotein 139-151(S) and desiccated Mycobacterium tuberculosis. On a clinical scale ranging from 0 to 5 EAE symptoms are assessed and body weight is monitored in a daily manner for at least thirty days.

The model can be used for the following fields of application:

  • Pharmacodynamics and pharmacokinetics
  • (Patho)physiological processes
  • Therapeutic efficacy
  • Proof of concept

Endpoints/Outcome parameter

  • Disease severity: level of disease (mean maximum clinical score, mean and median clinical score), extent of disease (total score, area under the curve), incidence, mean day of onset (in vivo)
  • Body weight (in vivo)
  • Central nervous system demyelination (ex vivo)
  • Infiltration of immune cells into nervous tissue (ex vivo)
  • Cytokine production

Readout parameter

  • Clinical score
  • Body weight
  • Histology (Luxol fast blue and various classical histological stains)
  • Immunohistochemistry
  • ELISA, qRT-PCR

Quality management and validation

  • Controls
  • Randomisation
  • Allocation concealment after immunization
  • Blinded data collection and analysis
  • Biometric Expertise
  • Internal quality management

Weblink(s)

https://www.izi.fraunhofer.de/de/departments/halle-location/department-of-drug-design-and-target-validation/molecular-biotechnology.html#tabpanel-2